A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Required: IDH1 wild-type

Must have received: radiation therapy

received prior treatment with at least radiotherapy

Must have received: alkylating agent (temozolomide)

received prior treatment with at least...temozolomide

Cannot have received: anticancer therapy

Exception: within 4 weeks (or five half-lives, whichever is longer) before starting the study treatment

Any anticancer therapies, including systemic, palliative, biologic, immunostimulatory, or immunosuppressive treatment within 4 weeks (or five half-lives, whichever is longer) before starting the study treatment

Cannot have received: immune checkpoint inhibitor (PD(L)-1/VEGF bispecific antibodies, CD137 agonists)

PD(L)-1/VEGF bispecific antibodies, cluster of differentiation (CD)137 agonists or other immune checkpoint blockade therapies including monotherapy with either category or combinations thereof

Cannot have received: systemic corticosteroid (dexamethasone)

Exception: at a dosage greater than 2 mg/day of dexamethasone or equivalent within 7 days before starting the study treatment

Systemic corticosteroids (at a dosage greater than 2 mg/day of dexamethasone or an equivalent dose of other corticosteroids) within 7 days before starting the study treatment

Cannot have received: antiplatelet drug (aspirin, clopidogrel, dipyridamole, ticlopidine, cilostazol)

Exception: aspirin (>325 mg/day), clopidogrel (>75 mg/day), dipyridamole, ticlopidine or cilostazol, etc., within 10 days before starting the study treatment

Antiplatelet drugs, such as aspirin (>325 mg/day), clopidogrel (>75 mg/day), dipyridamole, ticlopidine or cilostazol, etc., within 10 days before starting the study treatment

Cannot have received: investigational medicinal product

Exception: within five half-lives of the first dose or within 4 weeks, whichever is longer, before starting the study treatment

Any non-study investigational medicinal product within five half-lives of the first dose or within 4 weeks, whichever is longer, before starting the study treatment in this study or ongoing participation in the active treatment phase of another interventional clinical study

Cannot have received: interstitial brachytherapy

Have received prior interstitial brachytherapy

Cannot have received: interstitial thermal therapy

Have received prior...interstitial thermal therapy

Cannot have received: implanted chemotherapy (Gliadel wafers)

Have received prior...implanted chemotherapy...Participants who had prior treatment with Gliadel® wafers...are excluded

Cannot have received: therapeutics delivered by local injection or convection-enhanced drug delivery

therapeutics delivered by local injection or convection-enhanced drug delivery